PDCD4 and brain neoplasm: Down-regulation of PDCD4 expression was associated with unsatisfactory DSS in patients with head and neck cancers (HR: 5.05, 95% CI 1.12–62.50) [24], brain tumors (HR: 15.87, 95% CI 3.62–71.43) [33], and gynecologic cancers (HR: 3.36, 95% CI 1.43–7.81) [34].